成纤维细胞活化蛋白抑制剂PET/CT在非肿瘤疾病中的应用进展  

Application progress of fibroblast activation protein inhibitors PET/CT in non-tumor diseases

作　　者：郑钰州 施冬梅 郝新忠[1] 王红亮[1] Zheng Yuzhou;Shi Dongmei;Hao Xinzhong;Wang Hongliang(Department of Nuclear Medicine,First Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学第一医院核医学科,太原030001

出　　处：《国际放射医学核医学杂志》2024年第4期262-266,共5页International Journal of Radiation Medicine and Nuclear Medicine

基　　金：山西省基础研究计划(202103021224409);山西省研究生教育创新项目(2021Y434);山西省研究生教育教学改革课题(2021YJJG116)。

摘　　要：成纤维细胞活化蛋白(FAP)是一种具有二肽基肽酶和内肽酶活性的丝氨酸蛋白酶,常在肿瘤相关成纤维细胞中过表达。目前,放射性核素标记的成纤维细胞活化蛋白抑制剂(FAPI)PET/CT在肿瘤中的应用成为核医学研究的新热点。然而,FAP在活化的成纤维细胞中亦高表达,有关FAPI PET/CT在非肿瘤疾病(如心肌梗死、间质性肺纤维化疾病及免疫球蛋白G4相关疾病等)方面的研究取得了一定进展,且在疾病的早期诊断及疗效评估中具有潜在的应用前景。笔者就FAPI PET/CT在非肿瘤疾病中的应用及研究进展进行综述。Fibroblast activation protein(FAP)is a serine protease with dipeptidyl peptidase and endopeptidase activities,often overexpressed in tumor-associated fibroblasts.Currently,the use of radioisotope-labeled fibroblast activation protein inhibitors(FAPI)PET/CT in tumors has become a new hot spot in nuclear medicine research.However,FAP is also highly expressed in activated fibroblasts,and there has been some progress in the application of FAPI PET/CT in non-tumor diseases(such as myocardial infarction,interstitial pulmonary fibrosis diseases,and immunoglobulin G4-related diseases,etc),holding potential for in the early diagnosis and efficacy evaluation of these diseases.The authors review of the application and research progress of FAPI PET/CT in non-tumor diseases.

关 键 词：正电子发射断层显像术 体层摄影术 X线计算机 成纤维细胞活化蛋白 心肌纤维化 肺纤维化 肾脏纤维化 

分 类 号：R817.4[医药卫生—影像医学与核医学]